Breast cancer (metastatic) - fulvestrant (TA239)
Fast, easy summary view of NICE guidance on 'advanced breast cancer'
NICE does not recommend fulvestrant instead of aromatase inhibitor drugs for postmenopausal women with locally advanced or metastatic breast cancer when the cancer:
- depends on oestrogen for growth and
- has returned or worsened after anti-oestrogen drugs.
Aromatase inhibitors and anti-oestrogens are types of drug used to treat breast cancer.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. It was not clear from the evidence whether fulvestrant works as well as other treatments available on the NHS. It was also uncertain whether fulvestrant provides enough benefit to patients to justify its high cost, so NICE did not recommend it.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: advanced breast cancer
- None found
This page was last updated: 10 October 2012
- Web format
- Full Guidance (PDF)
- TA239 Fulvestrant ar gyfer canser y fron sy'n ddatblygedig yn lleol neu'n fetastatig: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.